Firefly Neuroscience secures $12.4 million financing to enhance brain health technology and support commercialization efforts.
Quiver AI Summary
Firefly Neuroscience, Inc. has announced the closing of a financing deal valued at up to $12.4 million, which includes $2.4 million in senior secured convertible notes and an equity line of credit for up to $10 million. The funds will support the growth and commercialization of its FDA-cleared Brain Network Analytics (BNA™) technology, aimed at improving brain health outcomes for patients with neurological and mental disorders. Executive Chairman Greg Lipschitz stated that this financing bolsters Firefly's balance sheet and provides the necessary capital to pursue strategic commercial partnerships and enhance diagnostic capabilities for healthcare providers. The BNA technology utilizes artificial intelligence to analyze brain function, assisting clinicians in diagnosing and treating various disorders.
Potential Positives
- The closing of up to $12.4 million in financing strengthens Firefly's balance sheet, providing financial flexibility for growth and commercialization efforts.
- The funding will facilitate the strategic commercialization of the FDA-510(k) cleared Brain Network Analytics (BNA™) technology, targeting both pharmaceutical companies and medical practitioners.
- Firefly’s BNA™ technology enhances diagnostic capabilities for mental and cognitive disorders, which could significantly improve patient outcomes.
- The company’s 15-year history of building a comprehensive database of brain wave tests and achieving FDA clearance positions it strongly in the competitive landscape for neurological and mental health technologies.
Potential Negatives
- The announcement of a $12.4 million financing, primarily through convertible notes and an equity line of credit, may raise concerns about the company's reliance on external funding for growth and commercialization efforts.
- The emphasis on forward-looking statements and associated risks suggests uncertainty regarding the company's future performance and success in implementing its commercialization strategies.
- The reference to potential adverse reactions or changes to business relationships resulting from the completed merger with WaveDancer adds to investor concerns about the stability and effectiveness of the company's partnerships.
FAQ
What is Firefly Neuroscience, Inc. focused on?
Firefly Neuroscience, Inc. develops AI solutions to improve brain health outcomes for patients with neurological and mental disorders.
How much funding did Firefly recently secure?
Firefly secured up to $12.4 million in funding, including $2.4 million in senior secured convertible notes and a $10 million equity line of credit.
What is Brain Network Analytics (BNA™)?
BNA™ is Firefly's FDA-510(k) cleared technology that offers diagnostic insights into various neurological and mental health disorders using advanced AI techniques.
Who will benefit from Firefly's BNA™ technology?
The BNA™ technology aims to support pharmaceutical companies, neurologists, and psychiatrists in enhancing diagnosis and treatment of brain health conditions.
How does Firefly plan to use its recent funding?
The funding will be used for growth, commercialization of BNA™ technology, and general working capital purposes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the closing of up to $12.4 million consisting of $2.4 million up front in the form of senior secured convertible notes at $3.00 per share, subject to adjustment, and an equity line of credit (the “ELOC”) for up to $10 million. The proceeds from these financings will be used for growth, commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) technology, and general working capital purposes.
"The closing of this financing strengthens our balance sheet and provides us the financial flexibility to continue to execute on our growth strategy,” said Greg Lipschitz, Executive Chairman of Firefly. “The additional working capital will allow us to accelerate two strategic commercialization pathways for our BNA technology. Through partnering with neuroscience pharmaceutical companies and by supporting US neurologists and psychiatrists in the diagnosis and optimization of patient care, we are driven to improve outcomes for people suffering from brain health illnesses.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit
https://fireflyneuro.com/
for more information.
Forward-Looking Statements
Certain statements in this press release and the information incorporated herein by reference may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNA
TM
technology; risks related to Firefly’s ability to recognize the anticipated benefits of the merger (the “Merger”) with WaveDancer, Inc. (“WaveDancer”); risks related to Firefly’s ability to correctly estimate its operating expenses and unanticipated spending and costs that could reduce Firefly’s cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the Merger; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading “Risk Factors” in the in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
Firefly@KCSA.com
Media Contact
KCSA Strategic Communications
Raquel Cona, Vice President
(516) 779-2630
Rcona@KCSA.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
